Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Secondary Neoplasm

Cancer Family

Secondary Neoplasm

CI-CAN-00000050Explore in graph →

Non-malignant4,271 active trials56 approved drugs532 evidence items

NCIt: C36255

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14666
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 76–100 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
· Cancer · 2016 · PMID 27525386 · validated civic_curation pubmed
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
· Lancet Oncol · 2016 · PMID 27460442 · validated civic_curation pubmed
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
· J Clin Endocrinol Metab · 2005 · PMID 16174717 · validated civic_curation pubmed
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
· Gastroenterology · 2012 · PMID 22705007 · validated civic_curation pubmed
Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.
· Future Oncol · 2015 · PMID 26169997 · validated civic_curation pubmed
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
· Am J Surg Pathol · 2016 · PMID 26975036 · validated civic_curation pubmed
Integrative clinical and molecular characterization of translocation renal cell carcinoma.
· Cell Rep · 2022 · PMID 34986355

Showing 76–100 of 486 publications

← Previous
1
2
3
4
5
…
20
Next →

· validated civic_curation

Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands.

· Nat Commun · 2019 · PMID 30664630 · validated civic_curation pubmed

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

· Science · 2015 · PMID 25765070 · validated cbioportal_study pubmed

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

· N Engl J Med · 2018 · PMID 29658845 · validated civic_curation pubmed

A minority of cases of acinic cell carcinoma of the salivary glands are driven by an NR4A2 rearrangement: the diagnostic utility of the assessment of NR4A2 and NR4A3 alterations in salivary gland tumors.

· Virchows Arch · 2023 · PMID 36469101 · validated civic_curation pubmed

Nuclear NR4A3 Immunostaining Is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands.

· Am J Surg Pathol · 2019 · PMID 31094928 · validated civic_curation pubmed

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.

· Mol Cancer · 2022 · PMID 34980131 · validated civic_curation pubmed

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18073307 · validated civic_curation pubmed

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

· Ann Surg Oncol · 2011 · PMID 21594703 · validated civic_curation pubmed

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.

· Oncol Lett · 2014 · PMID 24396464 · validated civic_curation pubmed

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

· Neoplasia · 2009 · PMID 19794967 · validated civic_curation pubmed

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.

· Clin Cancer Res · 2013 · PMID 23620406 · validated civic_curation pubmed

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.

· J Pathol · 2002 · PMID 11793370 · validated civic_curation pubmed

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.

· Histopathology · 2010 · PMID 20840671 · validated civic_curation pubmed

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.

· Br J Cancer · 2011 · PMID 21730982 · validated civic_curation pubmed

The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.

· Thyroid · 2012 · PMID 22650231 · validated civic_curation pubmed

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

· J Clin Endocrinol Metab · 2003 · PMID 12727991 · validated civic_curation pubmed

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.

· Lancet Oncol · 2013 · PMID 23333114 · validated civic_curation pubmed

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.

· BMC Cancer · 2012 · PMID 22292935 · validated civic_curation pubmed